Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Atazanavir is an HIV medicine of the protease inhibitor group: it blocks the viral protease, the enzyme HIV needs to cut its proteins into working parts, so new virus particles cannot mature. It is taken with a booster and with other HIV medicines. It is sold as Reyataz, among other names.
Atazanavir blocks UGT1A1, the liver enzyme that clears bilirubin, so bilirubin often rises and can turn the skin and eyes yellow. This is harmless to the liver but a common reason people stop the medicine. People with two copies of the low-activity UGT1A1*28 version (the same gene behind Gilbert's syndrome, about 1 in 10 people of European ancestry) are much more likely to develop visible jaundice. CPIC and DPWG have published guidelines on UGT1A1 and atazanavir. Studies have also looked at ABCB1 and NR1I2, with weaker evidence.
Clinical guidelines that name a gene for Atazanavir. They sort people into groups by the gene copies they carry.
Every published finding on gene variants and Atazanavir. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
UGT1A1 UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*36, UGT1A1*37: Level 1A · replicated. Toxicity: HIV infectious disease, Hyperbilirubinemia. 17.
NR1I2 rs2472677: Level 3. Metabolism/PK: Acquired Immunodeficiency Syndrome, HIV infectious disease, Nephrolithiasis. 4.
UGT1A1 rs887829: Level 3. Other: HIV infectious disease. 3.
SORCS2 rs73208473: Level 3. Metabolism/PK: HIV infectious disease. 2.
Studies of how quickly the body processes this medication.
Studies of how much of the drug people needed or tolerated.
NR1I2 rs2472677: Genotype TT is associated with dose of atazanavir in people with HIV Infections.
SLCO1B1 rs4149056: Genotype TT is associated with dose of atazanavir in people with HIV Infections.
Studies of side effects in people carrying a variant.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Agenerase (Protease Inhibitors)
Crixivan (Protease Inhibitors)
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com